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Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by a broad spectrum of clinical 
and histological presentations, ranging anywhere from simple steatosis to steatohepati-
tis. Of the patients with NAFLD, only a small fraction goes on to develop inflammation 
and fibrosis (i.e. NASH). Hence, understanding the underlying molecular mechanisms, 
which play part in progression of NAFLD and determine the disease severity, is extremely 
important. Almost two decades ago, Day and colleagues first described the “two-hit 
hypothesis” to explain progression of NAFLD. However, since then, the advances in 
field of molecular research have identified that NAFLD development and progression 
involves complex interplay of numerous determinants, including gut-derived signals, 
endoplasmic reticulum stress, adipose-derived adipokines, nutritional factors, hormonal 
imbalances and components of innate immunity which act in concert on genetically pre-
disposed individuals to induce liver inflammation. This chapter reviews the different 
players of this “multiple-hit model”.
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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) encompasses a broad spectrum of clinical and 
histo-pathological presentations, ranging from simple steatosis to nonalcoholic steatohepa-
titis (NASH), the latter being characterized by inflammation, macrovesicular steatosis and 
apoptosis, with or without fibrosis. NAFLD can further progress to liver fibrosis, cirrhosis and 
hepatocellular carcinoma (HCC) [1]. The prevalence of NAFLD in Western countries ranges 
from 30–46% [2], whereas in Asian populations, it is about 15% [3]. About 30% of patients 
with NAFLD may have NASH [4].
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Regarding progression of NASH to cirrhosis, estimated 10% of patients with NASH can prog-
ress to decompensated liver disease over 10 years and about 25% of patients develop cirrhosis 
over a span of 9 years [5]. It is very important to understand and uncover the underlying 
molecular mechanisms which explain the variable incidence and severity of steatohepatitis 
in only few patients with NAFLD, while most patients with steatosis never progress to ste-
atohepatitis [6]. After Day and Colleagues first described “two-hit” model for pathogenesis 
of steatohepatitis in 1998, wherein steatosis (“first hit”) progresses to steatohepatitis due to 
rampant lipid peroxidation in liver (“second hit”) [7], recent advances in field of molecular 
research have identified numerous other culprits, collectively summed up in “multiple-hit” 
hypothesis [8]. The “multiple-hit” hypothesis examines multiple insults which act collectively 
and in-parallel on genetically predisposed individuals to induce development of NAFLD and 
expedite progression to further adverse pathologies. This chapter provides a review of litera-
ture for multiple culprits identified in development of NAFLD and NASH.
2. Development of hepatic steatosis
Several mechanisms are involved in development of hepatic steatosis [9–11], including 
increased fatty acid supply due to increased lipogenesis from both visceral and subcutane-
ous adipose tissue, increased dietary intake of fats, increased de novo hepatic lipogenesis, 
decreased free fatty acid oxidation, and decreased secretion of VLDL from liver. Increased 
free fatty acid delivery to liver and elevated de novo lipogenesis are major contributors to fatty 
acid accumulation in NAFLD.
Elevated hepatic de novo lipogenesis may be due to activation by transcription factors such 
as SREBP-1(activated by Insulin, regulated via Insulin Receptor Substrate (IRS) and maintains 
cellular cholesterol homeostasis), ChREBP (activated by glucose and increased hepatic de novo 
lipogenesis) and PPAR-γ. Studies have demonstrated that de novo lipogenesis in liver is ele-
vated in insulin-resistant state and NAFLD [12, 13].
2.1. Lipoapoptosis: free fatty acids and cholesterol
Free fatty acid and Cholesterol are considered main players in lipotoxicity. Increased concen-
tration of serum free fatty acids (16 Carbons and more; saturated or unsaturated) are seen in 
patients with NAFLD [14]. Apoptosis of hepatocytes, which is morphologic and pathologic 
feature of human NASH, is partly due to free fatty acids, as explained below.
Hepatocytes can undergo apoptosis via extrinsic pathway (activated by FAS ligand and tumor 
necrosis factor related apoptosis-inducing ligands) or intrinsic pathway (activated by intra-
cellular stress of membrane-bound organelle, such as mitochondria, endoplasmic reticulum 
and mitochondria) [15]. Free fatty acids can induce apoptosis via following mechanisms, as 
demonstrated in Figure 1:
• Mitochondrial pathway [16] (palmitic acid and stearic acid activate intrinsic apoptotic path-
way via C-jun N-terminal kinase and Bim, leading to Bax activation, mitochondrial per-
meabilization, release of cytochrome c, and activation of Caspase 3 and 7),
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• Induction of Bim expression [17] (palmitic acid and stearic acid can activate transcription fac-
tor FoxO3a, which further induces expression of pro-apoptotic protein Bim),
• Lysosomal pathway [18, 19]: Oleic acid and palmitic acid activate Bax which trans-locates 
to lysosomes, increases the permeability of lysosomes and causes release of cathepsin B, 
which further increase permeability of mitochondria and activates Caspases. Furthermore, 
Lysosomal permeabilization is also associated with activation of NF-κB, which results in 
generation of tumor necrosis factor-α (TNF-α) in hepatocytes,
• Endoplasmic Reticulum [20]:Palmitic acid and stearic acid lead to activation of Endoplasmic 
reticulum (ER) stress pathway, which can lead to apoptosis, as explained later,
• C-Jun N-Terminal Kinase: JNK belongs to family of intracellular mitogen-activated protein 
(MAP). The murine dietary models of obesity were associated with increased activation of 
JNK in liver [21]. JNK leads to activation of pro-apoptotic protein Bax [22] while it inacti-
vates anti-apoptotic protein, Bcl-2 [23]
• Death Receptors: Tumor Necrosis Factor Receptors, TNFR-1 and TNFR-2, and Fas are implicated 
in pathogenesis of steatohepatitis [24]. Obesity, being a chronic inflammatory state [25], is char-
acterized by infiltration of adipose tissue by macrophages which release of inflammatory me-
diators, including TNF-α [26], with increased levels of TNF-α being observed in obesity. Upon 
activation by TNF-α, TNFR-1 activates NF-κB which leads to activation of pro-inflammatory 
genes and further apoptosis, if NF-κB mediated survival signals are inhibited. TNF-α can also 
lead to JNK activation, which can also lead to apoptosis if its activation is sustained [15].
Fas is expressed on hepatocytes and upon binding by Fas ligand, it signals apoptotic cell 
death [15]. In dietary murine models, such as methionine and choline-deficient diet and 
Figure 1. The figure demonstrates different mechanisms by which fatty acids impart lipotoxicity to hepatocytes 
(copyright © 2008 Georg Thieme Verlag KG) [15] (permission requested from Thieme publications).
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high sucrose diet, steatosis is accompanied by increased expression of hepatic Fas [27], and 
increase in Fas expression confers increased Fas ligand-mediated apoptosis. Also, Mono-
unsaturated fatty acid, oleic acid, under the transcriptional control of JNK, increases the 
expression of Fas and TRAIL-R2 on hepatocytes [15]. This is another mechanism by which 
fatty acids impart sensitivity to death receptor mediated extrinsic pathway of apoptosis,
• Ceramide: Ceramides are composed of sphingosine and fatty acid, and availability of long 
chain fatty acids is a rate limiting step in synthesis of ceramide in ER [28]. In nutritional obe-
sity with associated elevation of palmitic acid and stearic acid, excess synthesis of ceramide 
is possible. Palmitic acid and stearic acid-induced de novo ceramide synthesis in hematopoi-
etic precursor cell line is associated with apoptosis. However, more studies are needed to 
highlight the exact contribution of ceramide to wide spectrum of NAFLD pathologies [29]
• Toll-Like Receptors: toll-like receptors (TLR) are family of pattern recognition receptors that 
respond to microbial pathogens by activating innate arm of immune system [15]. Palmitic 
acid activates TLR4, leading to activation of NK-κB. This leads to upregulation of its target 
genes- i.e. TNF-α and Interleukin-6 (IL-6)- in macrophages and adipocytes [30]. When a 
high-fat diet is fed to mice lacking TLR4, there is a lack of inflammatory gene expression 
induction by high-fat diet, pointing towards the role of TLR4 in hepatic inflammation seen 
in NASH [31].
• Oxidative Stress: Enhanced mitochondrial and microsomal fatty acid β oxidation and cy-
tochrome P450 (CYP2E1) induction can lead to oxidative stress via generation of Reactive 
Oxygen species (ROS), as observed in human models of steatohepatitis [15, 32]. 4-hydroxy-
2-noneal (HNE) and Thiobarbituric acid reacting substrate (TBARS), both markers of lipid 
peroxidation, are increased in patients with NAFLD and NASH [33, 34]. Thus, oxidative 
stress may contribute towards development of steatosis and steatohepatitis.
• Long chain poly unsaturated fatty acids (LCPUFA): Oxidative stress leads to depletion of n-3 
LCPUFA (e.g Eicosapentaenoic acid, EPA, and docosahexaenoic Acid, DHA) due to in-
creased peroxidation or defective desaturation processes. Depletion of n-3 LCPUFA leads 
to upregulation of lipogenic and glycogenic effects from SREBP-1c and down-regulation 
of fatty acid oxidation effects from peroxisome proliferator activated receptor-α (PPAR-α), 
ultimately promoting hepatic steatosis [35]. In addition, depletion of LCPUFA can also lead 
to insulin resistance due to disturbance in membrane mediated processes such as insulin 
signaling [36]. From dietary prospective, a study aimed at assessing the influence of high-
fat diet on Δ5 and Δ6 desaturase enzymes involved in LCPUFA formation, found that HFD 
lead to enhanced oxidative stress and macrovesicular steatosis, with diminution in desatu-
rase activity and hence, depletion of LCPUFA [37].
The role of cholesterol in lipoapoptosis requires special mention. In an analysis conducted on 
human liver samples, subjects with NAFLD and NASH exhibited almost a 2-fold increase in 
free cholesterol, as compared to controls [38]. Furthermore, in a study to evaluate the effect of 
dietary free cholesterol loading in rodents, rats fed high cholesterol diet developed microve-
sicular steatosis and were sensitized to apoptotic effect of TNF-α, which may explain the 
lipoapoptosis due to cholesterol [39].
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2.2. Triglycerides
Triglycerides are the main lipids stored in liver of patients with hepatic steatosis and recent 
studies suggest that triglycerides may in fact have protective functions. Diacylglycerol acyl-
transferase 1 and 2 (DGAT) catalyze final step in triglyceride synthesis. In a model of diet-
induced obesity, mice with over-expression of DGAT1 in adipocytes and macrophages were 
protected from macrophage activation and accumulation in white adipose tissue, and from 
systemic inflammation and insulin resistance [9, 40]. In another study, DGAT2 antisense oli-
gonucleotides lead to inhibition of triglycerides synthesis which improved liver steatosis but 
worsened liver damage, further strengthening the notion that liver triglycerides are protec-
tive in nature [41]. Thus, in summary, accumulation of triglycerides in liver might not actually 
be a pathology but in fact, an adaptive, beneficial response in situations where hepatocytes 
are exposed to toxic triglyceride metabolites and fatty acid excess due to increased caloric 
consumption [9, 42].
2.3. Inflammation leads to Steatosis or vice versa: chicken or the egg?
• Treatment with anti-TNF antibody and metformin (an anti-diabetic drug that inhibits he-
patic TNFα expression) in ob/ob mice (the laboratory model of nonalcoholic fatty liver 
disease) showed marked improvement in hepatic steatosis [43, 44].
• In patients with alcoholic steatosis, treatment with anti-TNF antibody can improve hepatic 
steatosis [45].
• Similarly, loss of Kupffer cells lead to decreased production of anti-inflammatory cytokine 
(IL-10), which lead to hepatic steatosis [46].
The above examples support the notion that Inflammation activates stress response in hepa-
tocytes, which leads to lipid accumulation. In fact, hepatic steatosis may be considered a 
“bystander phenomenon” following inflammatory attacks. It may be a possibility that inflam-
mation proceeds steatosis in NASH and, benign and non-progressive simple steatosis and 
NASH are different disease entities altogether [9].
2.4. Insulin resistance in NAFLD
NAFLD is strongly associated with hepatic and adipose tissue insulin resistance, as well as 
reduced whole body insulin sensitivity [47]. Different underlying molecular mechanisms 
have been identified which account for insulin resistance [8]:
1. Serine phosphorylation of insulin receptor substrate (IRS) by inflammatory signals, such 
as c-jun N-terminal protein kinase 1 (JNK) or inhibitor of nuclear factor-jB kinase-b (IKKb) [48]
2. Activation of nuclear factor kappa B (NF-κB) and Suppressors of cytokine signaling (SOCS) [49]
Insulin Resistance would mean that ability of Insulin to suppress lipolysis has been supressed, 
leading to increased delivery of free fatty acids to liver [50]. The free fatty acid can further 
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exacerbate hepatic insulin resistance by causing translocation of PKC-γ isoform from cytosol 
to the membrane where it impairs hepatic insulin receptor substrate (IRS)-associated phospha-
tidylinositol activity [51].
2.4.1. Oxidative stress and insulin resistance
Prolonged excess oxidative load in steatosis, due to carbohydrates and lipids, leads to redox 
disequilibrium characterized by lower than normal hepatic anti-oxidative potential, for exam-
ple, decreased hepatic glutathione (GSH) and reduced superoxide dismutase (SOD) activ-
ity, which further triggers insulin resistance (IR) [52]. This is validated by a data from study 
where increased reactive oxygen species (ROS) in 3T3-L1 cultured pre-adipocytes preceded 
the onset of Insulin resistance [53], by molecular mechanisms listed above. The insulin resis-
tance due to exacerbated hepatic oxidative stress can in turn lead to upregulation of pro-
oxidative CYP2E1 expression, the response which is normally attenuated by repressive effects 
of Insulin on CYP2E1 expression [54]. Thus, there is increasing evidence for positive reinforce-
ment and interdependency between oxidative stress and insulin resistance in patients with 
Hepatic steatosis [52].
Thus, due to impairment in IRS activity and further down-regulation of IRS due to insulin 
resistance, SREBP is unregulated and over-expressed, leading to increased hepatic de novo 
lipogenesis [55]. Insulin Resistance, due to its ability to induce lipotoxicity, oxidative stress 
and inflammatory cascade, may be one of the “multiple hit” in pathogenesis of NAFLD and 
progression towards NASH [8, 56].
3. The gut-derived factors
The gut microbiota is implicated in the pathogenesis and progression of NAFLD, through so-
called gut-liver axis [8]. A study aimed at analyzing human gut microbiome recognized dif-
ferent “enterotypes” [57] and “obese microbiome”, which has an ability to harvest increased 
amount of energy from diet, has been demonstrated in obese mice [58]. In fact, colonization 
of germ-free mice with “obese microbiome” leads to greater increase in total body fat as com-
pared to colonization with “lean microbiome” [58]. The Figure 2 summarizes the role of gut-
liver axis and adipose tissue in pathogenesis of NAFLD.
The liver receives more than 50% of its blood supply from splanchnic circulation [8], and hence, 
it is always exposed to gut-derived toxins. The ability of gut-derived factors like lipopolysaccha-
ride (LPS) to flow in portal vein requires intestinal permeability, which in NAFLD is due to dis-
rupted intercellular tight junctions in the intestine [59]. In Murine models of NAFLD, intestinal 
mucosa has bacterial overgrowth with increased intestinal permeability and concurrent reduc-
tion in expression of tight junction proteins [60]. Consequentially, plasma endotoxin levels are 
significantly high in patients with NAFLD and NASH [61], and high-fat diet is associated with 
2–3 fold increase in plasma LPS levels [62]. LPS may act as a ligand for TLR with consequent 
activation of inflammatory cascade, including stress- and mitogen-activated protein kinases- 
JNK (explained later), p38, Interferon regulatory factors 3 and nuclear factor-jB – each having 
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Figure 2. “The multiple parallel hits model. Lipotoxicity: (1) a liver loaded with lipids consisting primarily of trigylcerides 
might reflect a benign process because triglycerides might exert mostly protective effects. Furthermore, hyperleptinemia 
leads to oxidation of hepatic lipids, thereby also protecting this organ from lipotoxicity. When the capacity of peripheral 
and central organs of detoxifying “aggressive lipids” fails, lipotoxic attack of the liver might begin. Inflammation may 
precede steatosis in NASH. Gut-derived signals: Many signals beyond endotoxin might affect hepatic steatosis and 
inflammation. Several pathways have been identified how the gut microbiota might influence host energy metabolism: 
(2) Absence of the microbiota in germ-free mice correlates with increased activity of phosphorylated AMPK in the liver 
and the muscle (not shown). (3) Some of the breakdown products of polysaccharides are metabolized to SCFAs. SCFAs 
such as propionate and acetate are ligands for the G protein-coupled receptors Gpr41 and Gpr43. Shortage of SCFAs 
might allow the evolution of systemic inflammatory events. Such mechanisms elegantly combine diet, microbiota, and 
the epithelial cell as “nutrient sensor.” (4) The microbiota decreases epithelial expression of fasting-induced adipocyte 
factor (Fiaf), which functions as a circulating lipoprotein lipase (LPL) inhibitor and therefore is an important regulator 
of peripheral fat storage. (5) Several TLRs, such as TLR5 or TLR9, are not only able to affect microbiota but also to 
regulate metabolism, systemic inflammation, and insulin resistance, thus highlighting the role of the innate immune 
system in metabolic inflammation as observed in NASH. (6) Various nutrients such as trans fatty acids (TFAs), fructose 
or aryl hydrocarbon receptor (AhR) ligands such as 2,3,7,8-tetrachlorodibenzodioxin (TCDD) may directly lead to 
steatosis/liver inflammation. Adipose tissue-derived signals: Signals derived from the adipose tissue beyond toxic 
lipids might play a central role in NAFLD/NASH. (7) here, adipocytokines such as adiponectin and leptin, certain pro-
inflammatory cytokines such as TNFα or IL-6, and others (the death receptor Fas, PPARγ) are of key relevance. The 
cytokine/adipocytokine milieu might be critical because ob/ob-adiponectin tg mice, although becoming severely obese, 
are not insulin-resistant. This suggests that in the hierarchy of processes soluble mediators play the central role. Adipose-
derived mediators might indeed affect target organs such as the liver, because JNK1 adipose-deficient mice are protected 
from diet-induced obesity, and experiments have demonstrated that this effect is mediated mainly by IL-6 (a cytokine), 
which is of key importance in human obesity.” [9] (figure and associated caption used after permission from “John Wiley 
and Sons” [9]).
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significant contribution towards insulin resistance, hepatic fat accumulation, obesity and NASH 
development and progression [63, 64]. Evidently, a continuous infusion of LPS for 4 weeks in 
mice mimicked high-fat diet phenotype, with noticeable increase in insulin resistance, increased 
liver triglyceride content and adipose tissue inflammation [62]. Similarly, the use of antibiotics 
reduced the intensity of inflammation in high-fat diet and ob/ob mice [65].
Another mechanism for gut microbiota to influence the host immune system is via their 
capacity to digest dietary fibers, such as resistant starch and nonstarch polysaccharide, to short 
chain fatty acids (SCFAs, mainly propionate, butyrate and acetate), which are absorbed by 
intestinal epithelium [66]. SCFAs, via their interactions with G protein-coupled receptor 
43 (Gpr43), have anti-inflammatory function in various models of human ulcerative colitis 
[67, 68].
Enteric bacteria also suppress the synthesis of fasting-induced adipocyte factor (Fiaf), result-
ing in increased lipoprotein lipase activity and increased triglyceride accumulation in the 
liver [8, 9]. Gut microbiota also produce enzymes which cause the conversion of dietary cho-
line to toxic compounds, particularly methylamines which, in the liver, are transformed to 
trimethylamine-N-oxide and induce inflammation and liver fibrosis [69]. Intestinal microbi-
ome is a major source for production of hepatotoxic compounds such as alcohol, phenols and 
ammonia which are delivered to the liver by portal circulation. These compounds activate 
kupffer cells and stimulate the production of nitric oxide and other inflammatory cytokines 
[70]. Patients with NASH show abundance of alcohol-producing bacteria as compared to 
healthy children and children with simple steatosis [71]. This endogenous production of alco-
hol has a well-established role in generation of ROS and liver inflammation [72].
Furthermore, NLRP6 and NLRP3 inflammasomes, through their production of IL-18, play an 
important role in modulation of gut microbiota. In different mouse models, inflammasomes 
deficiency is associated with modifications in configuration of gut microbiota, and exacerba-
tion of hepatic steatosis and inflammation. This is due to increased influx of TLR4 and TLR9 
ligands into the portal circulation, leading to enhanced tumor necrosis factor-α (TNF-α) pro-
duction in liver which leads to NASH progression [73].
3.1. Bile acids
The primary bile acids cholic acid and chenodeoxycholic acid are conjugated to glycine and 
taken up in distal ileum for transport to the liver [74]. By binding to cellular receptor farne-
soid X receptor (FXR) in various organs of the body, bile acids act as signaling molecules to 
control overall metabolism of the host [75]. Upon activation of FXR by primary bile acids, 
downstream signals are generated which lead to inhibition of hepatic de novo lipogenesis, 
increased insulin sensitivity and protection of hepatocytes from bile acid-induced cytotox-
icity [76]. However, the gut microbiota in distal ileum can deconjugate the bile acids and 
can further metabolize them to secondary bile acids, and thus, contribute towards obesity 
by altering lipid metabolism, through changes in bile acid pools and modulation of FXR 
signaling [74].
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3.2. Dietary factors
The recent decades saw a dramatic increase in consumption of trans-fatty acids, and as evi-
dent from studies on mice, trans-fatty acids consumption leads to larger liver with NASH-
like lesions and Insulin resistance [77]. Similarly, Fructose is a lipogenic, pro-inflammatory 
dietary factor associated with oxidative stress and upregulation of TNF-α [78], and daily 
fructose consumption is associated with liver inflammation and fibrosis [79]. Fructose diet 
can induce oxidative stress and hepatocellular damage by different mechanisms, including 
induction of protein fructosylation which activates SREBP and generates reactive oxygen spe-
cies (ROS) [80]. Also fructose phosphorylation leads to depletion of ATP, which stimulates 
increased uric acid synthesis which in turn stimulates production of ROS [81]. Lastly fruc-
tose can induce mitochondrial disturbance which lead to disequilibrium between De novo 
Lipogenesis and VLDL, which promotes alteration of respiratory chain and uncoupling of oxi-
dative phosphorylation with excess ROS production [82, 83].
Another receptor, aryl hydrocarbon receptor (AhR), is a ligand activated transcription factor which 
is activated by many constituents of our diet such as indolo-(3,2-b)-carbazole and 3,3′-diindolyl-
methane (metabolized from indole 2-carbinol), or flavonoids, and this pathway plays an impor-
tant role in inflammation [84]. This is evident in transgenic mice with constitutively activated AhR 
as they develop spontaneous hepatic steatosis and increased hepatic oxidative stress [85].
Studies show that Low-Calorie, Low-carbohydrate soy-containing diet and Mediterranean 
diet rich in antioxidants and polyunsaturated fatty acids of n-3 series are known to be protec-
tive in reducing hepatic steatosis [86].
4. Adipose tissue-derived signal
Adipose tissue, with its ability to generate cytokines and adipocytokines, can be classified as 
a complex endocrine and immune organ which mediates different metabolic, immunological 
and inflammatory responses.
4.1. Adiponectin
Adiponectin is an anti-inflammatory cytokine with anti-lipogenic effects which protect non-
adipocyte tissue, such as liver, from lipid accumulation [87]. Reduced levels of adiponec-
tin are seen in conditions associated with development of NAFLD, namely obesity [88] and 
insulin resistance [89]. Hence, adiponectin levels are inversely related to visceral obesity and 
insulin resistance, and weight loss is an inducer of adiponectin synthesis [90]. The levels of 
adiponectin are significantly reduced in patients with NASH as compared to simple steatosis 
[91]. Thus adiponectin protects the liver against steatosis.
By activating cyclic-AMP dependent protein kinase (AMPK), adiponectin opposes fatty acid 
synthesis and promotes mitochondrial β-oxidation [92]. The anti-inflammatory effects of 
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adiponectin are due to its ability to block activation of NF-κB which inhibits the release of pro-
inflammatory cytokines such as TNFα and IL-6 [93]. The anti-inflammatory and hepatic lipid 
modulating effects of adiponectin may also be due to activation of peroxisome proliferator 
activated receptor-α (PPAR-α), as pharmacological treatment with PPAR-α agonist reverses 
experimental steatohepatitis [94]. Furthermore, PPAR-γ agonist, such as thiazolidinedione, 
stimulate adiponectin synthesis, and latter activates PPAR-α [95].
4.2. Leptin
Leptin is a gene product of ob gene and is produced by visceral adipocytes [96]. The levels 
of leptin directly correlate with body fat mass and adipocyte size [97]. Leptin has a potential 
dual action on NAFLD experimental models, exerting anti-steatotic, and pro-inflammatory/
pro-fibrogenic actions [98]. In non-adipose tissue, such as liver, it prevents lipid accumulation 
by decreasing the expression of SREBP-1. Leptin exerts pro-fibrogenic effects by activating 
stellate cell in liver through hedgehock [99], mTOR [100] or kupffer cell-mediated TGF-β1 
secretion which then activates stellate cell [101]. In mice models of NASH, gut-derived endo-
toxins can induce hyper-responsiveness to leptin, with subsequent upregulation of CD14 and 
accelerated fibrosis [102]. Experimental studies have demonstrated that leptin deficiency in 
mice may lead to hepatic steatosis which can be reversed by leptin replacement. On the other 
hand, excess leptin contributes towards hepatic inflammation and fibrosis [98]. It may be a 
possibility that anti-steatosis effects of leptin may predominate in initial stages of NAFLD 
while pro-inflammatory and pro-fibrotic effects might take over during disease progres-
sion phase [103]. However, the exact magnitude of contribution by Leptin towards NAFLD 
remains to be elucidated.
4.3. IL-6 and TNFα
In severe obesity, adipocytes are major source of IL-6 production, as evident by a study 
results where IL-6 expression was 100-fold elevated in adipose tissue as compared to 
liver in obese patients [9]. Similarly, elevated TNF-α production has been observed in 
cultures of peripheral blood cells collected from obese patients with NASH [104]. These 
two important pro-inflammatory cytokines are found to be elevated in obese patients 
and weight loss is associated with dramatic decrease in serum levels of these cytokines 
[105, 106].
The liver is the target organ for adipose tissue-derived 1 L-6 and TNFα. It is known that 
high-fat diet, also called “inflammatory diet”, stimulates JNK1 (mitogen-activated protein 
kinase, associated with apoptosis) signaling in adipocytes, which leads to IL-6 secretion by 
adipocytes. IL-6 further acts on hepatic cell, leading to hepatic steatosis and hepatic insulin 
resistance [48]. Continuous exposure to elevated levels of IL-6/TNF-α leads to many of the 
histological features of NASH such as hepatocyte necrosis and apoptosis, neutrophil che-
motaxis and activation of hepatic stellate cells [107]. Also, they caused insulin resistance by 
upregulating hepatic suppressor of cytokine signaling 3 (SOCS3) [108].
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Transcription factor nuclear factor-jB kinase b (NF-κB) and its IKK2 subunits is also important 
mediators of chronic inflammatory states. Persistent activation of NF-κB has been shown in 
animal models of NAFLD [109] and NASH [110].
4.4. Inflammasomes
Inflammasomes are large caspase-1 –activating multiprotein complexes that sense both endog-
enous and exogenous danger signals via intracellular NOD-like receptors (NLRs) [111]. Among 
the three prototypes of inflammasomes, NALP3 is associated with NAFLD and responds to 
danger signals by activating Caspase 1. Active Caspase-1 promotes cleavage and maturation 
of pro-inflammatory cytokines, such as IL-1β, IL-18, IL-33, which further promote inflamma-
tion [111]. Gut-derived endotoxin and free fatty acid may act as danger associated molecular 
pattern (DAMP) which may lead to activation of inflammasomes [112].
To validate the role of inflammasomes in NASH, it was seen that there was increased gene 
expression of inflammasomes in livers of patients with NASH as compared to liver of healthy 
controls [113]. Furthermore, LPS and saturated fatty acids amplify the expression and activa-
tion of inflammasomes, and free fatty acids sensitize the hepatocytes to LPS-induced IL-1β 
secretion [112]. It was seen observed that saturated fatty acids also directly induce hepatocyte 
apoptosis and activation of Caspase 8, which triggers the release of danger molecules from 
hepatocytes [112].
IL-1β induces the suppression of peroxisome proliferator activated receptor-α (PPAR-α), acti-
vates the stellate cells to promote fibrosis and promotes TNF-α-induced cell death [114].
5. Toll-like receptors and innate immunity
Toll-like receptors are sensors of microbial and endogenous danger signals which are expressed 
in innate immune cells and liver parenchyma and contribute towards progression of NASH 
[90]. Upon activation by gut microbiota-released pathogen- or damage- associated molecular 
pattern (PAMP and DAMP), downstream signals are activated which lead to progression of 
NASH. TLR2, TLR4 and TLR9 are most commonly associated with NASH [90].
The gut-derived bacterial endotoxin is brought to liver via portal circulation where they acti-
vate the kupffer cell by way of TLR4 receptor complex. This interaction leads to activation of 
nuclear transcription factors, leading to release of pro-inflammatory mediators such as TNFα 
which can induce liver injury and fibrosis [115]. The role of TLR4 in pathogenesis of NASH 
is further supported by study where TLR4-deficient mice, which were fed high fructose 
diet,were protected from formation of reactive oxygen species, induction of TNFα expression 
in liver and insulin resistance [116].
TLR9 is located on endoplasmic reticulum and is activated by unmethylated CpG DNA par-
ticles that are released from bacteria [90]. It is known that TLR9 is involved in steatohepatitis 
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as TLR9-deficient mice are protected from liver inflammation [114]. In CDAA diet-(Choline- 
deficient amino acid defined diet) induced NASH, translocated bacterial DNA from gut 
binds to TLR9 receptor on kupffer cell to produce IL-1β which activate hepatic stellate cells 
to induce liver fibrosis, and also stimulate hepatocytes for lipid accumulation and cell death 
[114]. The induction of hepatic steatosis is independent of TLR2, however, functional TLR2 
receptors are found on kupffer cells which mediate liver inflammation and fibrosis in CDAA 
diet-induced NASH [117].
Recently, another data that implicated TLR5 in pathogenesis of metabolic syndrome was 
presented. It was reported that mice deficient in TLR5 developed all features of metabolic 
syndrome including, hyperphagia, obesity, insulin resistance, pancreatic inflammation and 
hepatic steatosis. It was proposed that TLR5 altered the gut microbiota and the finding were 
reproducible when microbiota from TLR5 −/− mice was transferred to healthy mice [118]. 
However, another study did not find any such results in TLR5-deficient mice [119]. Indeed, 
more studies are needed to elicit role of TLR5 in steatohepatitis.
6. Endoplasmic reticulum (ER) stress
Endoplasmic reticulum (ER) is an important intracellular organelle involved in production, 
folding, post-translational modification and trafficking of secretory and membrane proteins. 
Also present in the ER is endoplasmic reticulum-associated degradation (ERAD) machinery 
that ensures that misfolded proteins are re-translocated back to cytoplasm for degradation by 
proteasomes [120]. Thus, ER serves as a quality control checkpoint, allowing only properly 
folded proteins to be transported to Golgi apparatus [121, 122] (Figure 3).
Any event that disturbs ER protein folding capacity- be it due to excessive protein synthesis, 
accumulation of misfolded proteins, depletion of calcium in ER, disturbance in redox regula-
tion, glucose depletion, viral infection or high-fat diet (saturated fatty acid such as palmitic 
acid and stearic acid) [123] - leads to induction of evolutionarily conserved ER stress response, 
known as Unfolded protein response (UPR). The role of sensing ER stress and activating UPR 
is performed by three ER transmembrane proteins, mentioned as following:
1. RNA-dependent Protein kinase-like ER eukaryotic initiation factor-2α Kinase (PERK)
2. Inositol-requiring ER-to-nucleus signaling protein1 (IRE1) and,
3. Transcription factor 6 (ATF6)
Each of these transmembrane proteins has an ER luminal domain to sense unfolded protein, a 
transfolded domain for targeting to the ER membrane, and a cytosolic domain to transmit sig-
nals to the transcriptional and/or translational apparatus [124]. In an unstressed cell, these ER 
proteins are maintained in an inactive state via their association with the ER chaperon protein, 
glucose-regulated protein 78 (GRP78)/Bip [125] and upon ER stress, unfolded/ misfolded pro-
teins accumulation enhances the release of GRP78 from these stress-sensing proteins, leading 
to respective activation of PERK, ATF6 and IRE1 [126].
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Upon activation, PERK, IRE1α and ATF6 induce signal transduction events that attenuate the 
accumulation of misfolded proteins in the ER by increasing expression of ER chaperons, inhib-
iting protein load on ER by decreasing mRNA translation, and stimulating retrograde trans-
port of misfolded proteins from ER into cytosol for ubiquination and destruction by a process 
named ERAD [127]. However, under conditions where ER stress is chronically prolonged and 
the cell fails to restore homeostatsis in ER, the UPR will initiate cell apoptosis [126].
6.1. Protein kinase RNA-like endoplasmic reticulum kinase (PERK)
Activation of PERK leads to phosphorylation of α-subunit of eukaryotic Initiation Factor 
2α (eIF-2α), leading to its inactivation and hence, attenuation of mRNA translation and 
decreased protein load on the ER [128]. The phosphorylated eIF-2α also causes preferen-
tial translation of UPR-dependent genes, such as activation transcription factor 4 (ATF 4). 
Further, ATF4 induces expression of several genes, including amino acid transporter, chap-
erons and CHOP [129] (“C/EBP homologous protein”, also known as ‘growth arrest and DNA 
damage (GADD 15)).
Figure 3. The figure demonstrating the three different pathways of unfolded protein response [135] (https://doi.
org/10.1016/j.jhep.2010.11.005) (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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CHOP is an ER-derived transcription factor which is an important mediator of ER stress-
induced apoptosis, as evident from studies where deletion of CHOP lead to attenuation of 
hepatocellular apoptosis in alcohol- and cholestasis-induced liver disease [130]. Apoptosis-
relevant targets of the CHOP transcription factor include:
1. GADD34 [131]: promotes dephosphorylation of eIF2α,thus reversing translation inhibi-
tion. This leads to accumulation of unfolded proteins in ER compartment, and, simultane-
ously, permits translation of mRNA encoding pro-apoptotic genes,
2. DR5: a caspase activating cell-surface death receptor, and 
3. Ero 1 α (Endoplasmic Reticulum Oxidoreductase-1): hyperoxdises the ER and also acti-
vates the inositol triphosphate receptor (IP3R), causing excessive transport of Calcium from ER to the mitochondria and thus causing cell death) [132].
CHOP also induces apoptosis via direct inhibition of Bcl-2 transcription [133] and induction of 
Bim expression [134]. Bcl-2 proteins are localized within the ER membrane and are protective 
(anti-apoptotic) against ER stress. This cytoprotective function is mainly due to the ability of 
Bcl-2 to lower steady-state levels of ER Ca2+ via IP3Rs. The protective role of Bcl-2 in regulating ER Ca2+ can be inhibited by JNK-mediated phosphorylation of Bcl-2. The Phosphorylated Bcl-2 
loses its anti-apoptotic function by being unable to bind pro-apoptotic “BH3-only” members of Bcl-2 family (i.e. Bim), leading to increasing calcium release from ER, which is associated 
with mitochondrial calcium uptake. This leads to increased mitochondrial permeabilization, 
release of cytochrome C, and hence apoptosis [127]. Calcium release from ER can also activate 
Caplains, which may further proteolytically activate Caspase-12 to induce apoptosis [135].
6.2. Inositol-requiring ER-to-nucleus signaling protein1 (IRE1)
Accumulation of unfolded proteins in ER leads to activation of IRE1, which further processes 
an intron from X-box binding protein-1 (XBP-1) mRNA and permits synthesis of XBP-1 protein. 
XBP-1 binds to promoters of genes involved in UPR (encoding ER chaperons) and ERAD to 
restore homeostasis and prevent cellular toxicity [127]. Apart from cytoprotective effects, IRE1 
can also recruits inflammatory factors (JNK and NF-κB) which induce inflammatory response 
signaling [136], and apoptotic signal kinase-1 (ASK1) which causes downstream activation of 
stress kinases Jun-N-terminal Kinase (JNK) and p38 MAPK, that promotes apoptosis [137].
Activated JNK translocate to mitochondria and causes activation of Bim and Inhibition of 
Bcl-2. Activated JNK also induces the expression of pro-inflammatory genes by phosphorylat-
ing transcription factor activating protein-1(AP-1) [138]. Activated p38 MAPK phosphorylates 
and activates CHOP [127] to causes apoptosis.
6.3. Transcription factor 6 (ATF6)
ATF6 belongs to CREB family of transcription factors. Activation of ATF6 leads to its release 
from ER membrane, processing in the Golgi and entry into the nucleus. It trans-activates ER 
stress related genes such as ER chaperones, XBP-1, foldases and CHOP [124].
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6.4. Endoplasmic reticulum stress and Steatosis
Hepatocytes, being rich in both smooth and rough EPR, perform diverse metabolic functions, 
including lipoprotein and very-low-density lipoprotein (VLDL) assembly and secretion, cho-
lesterol biosynthesis and xenobiotic metabolism [121]. The Sterol regulatory element-binding 
protein (SREBPs) are key regulators of lipid homoeostasis and play crucial role in de novo 
lipogenesis [139], where SREBP-1 regulates fatty acid and triglycerides (TG) metabolism and 
SREBP-2 controls cholesterol metabolism and low density lipoprotein (LDL) receptor expres-
sion [140]. SREBP are transcription factors bound to ER membrane in inactive form and their 
activity is controlled within ER by interaction of SREBP-Cleavage Activating Protein (SCAP) 
and Insulin regulated proteins (Insigs). Insigs cause SREBP-SCAP complex to be retained within 
the ER and prevents SREBP-1 activation [141]. Under conditions of low sterols, Insigs are dis-
sociated with SCAP, leading to migration of SREBP-SCAP complex to Golgi apparatus, where 
SREBP is processed to its active form by S1P and S2P [142]. Activated SREBP translocate to 
nucleus and regulates the various genes involved in lipid metabolism.
However, under ER Stress, rapid activation of precursor form of SREBP-1c and SREBP-1c 
target genes takes place, even in absence of Insulin [143]. Furthermore, ER stress induces 
proteolytic activation of SREBPs by increasing turnover of Insigs [142]. Hence, the recent data 
suggests that ER stress leads to hepatic steatosis by increasing de novo lipogenesis and upreg-
ulating the transcription of genes encoding for key lipogenic trans-activators and enzymes 
[121, 144].
Due to its high capacity for protein synthesis, ER stress plays an important part in mediating 
pathological changes in various liver diseases [135]. The signaling pathway activated by ER 
stress are implicated in lipotoxicity, Insulin Resistance, Inflammation and apoptotic cell death 
which are common to both NAFLD and NASH [123]. The presence of ER stress and activa-
tion of UPR in chronic disease (such as NAFLD) suggests that ability to resolve ER stress has 
been compromised. Inducing ER stress in individuals with genetically ablated eIF2α, IRE1α 
or ATF6α leads to hepatic steatosis [145], suggesting that steatosis results from impairment 
in the capacity to oxidize fatty acids and augmented by impaired lipoprotein secretion. Thus, 
initially UPR aims to prevent steatosis and re-establish ER homeostasis after ER stress but selec-
tive impairment to the UPR that reduce the ability of UPR to resolve ER stress leads to devel-
opment and exacerbation of hepatic steatosis. However, further work is needed to investigate 
this Homeostatic Model hypothesis.
It is now well-established that various arms of UPR and its downstream signaling molecules 
play role in regulation of lipid metabolism and induction of various hepatic pathologies.
6.4.1. PERK-eIF2α-ATF4 pathway
The PERK-eIF2α-ATF4 pathway is reported to regulate lipogenesis and hepatic steatosis. 
PERK-dependent signaling has been crucial to sustained expression of lipogenic enzymes 
such as fatty acid synthase (FAS), ATP-citrate Lyase, and stearoyl-CoA Desaturase-1(SCD1) 
[146]. Phosphorylated eIF2α (activated form) is associated with enhanced expression of adipo-
genic nuclear receptor peroxisome proliferator activated receptor γ (PPAR γ) and its upstream 
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regulators, and dephosphorylation of eIF2α using GADD34 leads to diminished hepatoste-
atosis in animals fed high-fat diet [147]. Furthermore, activated ATF4 increases expression of 
lipogenic genes, such as PPAR γ, sterol regulatory element-binding protein-1c (SREBP-1c), ace-
tyl-CoA carboxylase (ACC), and FAS, in liver and white adipose tissue. Similarly, ATF4 knock-
out mice are protected from diet-induced hepatic steatosis [148, 149]. Thus, the current evidence 
suggests that PERK-eIF2α-ATF4 pathway plays an important role in promoting lipogenesis.
6.4.2. IRE1α-XBP1 pathway
The IRE1α-XBP1 pathway plays an important part in maintenance of hepatic lipid homeo-
statsis under ER stress and regulation of hepatic VLDL assembly and secretion [150]. IRE1α 
is also required for efficient synthesis of ApoB-containing lipoproteins [151]. Mice with hepa-
tocyte specific deletion of IREIα show increased hepatic steatosis and reduced plasma lipids 
under ER stress condition due to altered expression of key metabolic players (such as PPARγ 
and C/EBPβ) and of enzymes involved in Triglycerides biosynthesis [151]. Thus, these results 
indicate IRE1α represses lipid accumulation in liver, especially under ER stress condition. 
However, the deletion of IRE1α leads to loss of this protective role of IRE1α, resulting in 
unresolved ER stress and hence, hepatic steatosis.
The role of XBP1 in lipogenesis is emphasized in a study where conditional disruption of 
XBP-1 in the liver of mice lead to reduced plasma level of triglycerides, cholesterol and 
free fatty acids, possibly due to decreased de novo lipogenesis [152]. XBP1 regulates lipo-
genesis in hepatocytes by directly binding to promotors of lipogenic genes such as SCD1 
(Stearoyl-CoA Desaturase 1), DGAT2 (Diacylglycerol Transferase 2) and ACC2 (Acetyl-CoA 
carboxylase),thereby activating their transcription [152]. Thus under appropriate conditions, 
XBP1 promotes lipogenesis and contributes to hepatic lipogenesis.
6.4.3. Transcription factor 6 (ATF6)
ATF6 and SREBP are both ER membrane bound transcription factors, and nuclear ATF6 inter-
acts with nuclear SREBP 2, antagonizing the SREBP2- regulated transcription of lipogenic 
genes and preventing lipid accumulation in cultures of liver cell [153]. Moreover, ATF2α-
knockout mice develop hepatic steatosis in response to ER stress, due to reduced fatty acid 
oxidation and decreased VLDL secretion [154].
Thus, taken together, all three proximal UPR sensors including PERK, IRE1α and ATF6α, 
regulate lipid stores in liver but the degree to which the UPR contributes to hepatic steatosis 
may depend on activation of three proximal UPR sensors relative to each other, coupled with 
appropriate downstream protein–protein and/or protein-DNA interaction [120].
6.5. Endoplasmic reticulum stress and progression towards NASH
Multiple factors, including but not limited to, insulin action, oxidative stress, cytokine medi-
ated signaling, inflammation, bacterial endotoxin, and excess fatty acids function in concert 
and interact with UPR to provoke disease progression of NAFLD towards NASH.
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6.5.1. ER stress and hepatic inflammation
Several Signaling pathways connect ER stress to hepatic inflammation:
• Reactive oxygen species (ROS)
Protein folding in ER is intimately linked to generation of ROS, such that each disulfide 
bond formation during oxidative protein folding leads to production of 1 ROS [155]. An 
elevated protein folding load, as in ER stress, leads to accumulation of ROS, which may 
lead to inflammation. In turn, the oxidative stress from ROS can disrupt ER homeostasis 
and induce ER stress [156].
However, in an unsurprising adaptive pathway, UPR activates an antioxidant program 
via transcription factor Nrf2 (nuclear factor erythroid-derived 2-related factor 2) to prevent 
accumulation of ROS [157]. Nrf2 is activated after phosphorylation by PERK pathway of 
UPR and it regulates the inducible expression of anti-oxidant response element-containing 
genes [157]. Importantly, Nrf2 deletion results in rapid onset and progression of steato-
hepatitis in mice provided a methionine choline-deficient (MCD) diet [158]. ATF4, one of 
the other terminal player of PERK pathway, has also been an important transcription factor 
in maintenance of adequate Glutathione levels in cells [159]. Thus, PERK arm of UPR and 
its downstream players are directly related to regulation of anti-oxidant effects. In a re-
cent study, IRE1α-XBP1 branch of UPR was also found linked to anti-oxidant effect, where 
XBP1 deficiency leads to reduced catalase expression [160].
• NF-κB and JNK
In response to ER stress, IRE1α binds to adaptor protein tumor-necrosis factor α (TNF-α) 
receptor-associated factor 2 (TRAF2). IRE1α-TRAF2 complex activates NF-κB and JNK, 
both of which induce production of Pro-inflammatory cytokines, such as C-reactive protein 
(CRP), amyloid P-component, fibrinogen, and interleukin-6 (IL-6) [161].
The UPR-mediated signaling can lead to activation of NF-κB not only via IRE1α but also 
via PERK [162] and/or ATF6 pathway [163]. Activation of NF-κB has been detected in ste-
atohepatitis induced by MCD diet, however, the exact mechanism about how ER stress-
induced signaling involving NK-κB and JNK might regulate inflammation, cell survival 
and apoptosis in NAFLD is still unknown.
• PKR (double-stranded RNA-activated Protein Kinase)
PKR is an interferon-induced Serine/threonine protein kinase, activated by dsRNA, and is ca-
pable of activating NF-κB and eIF2α in response to dsRNA and oxidative stress, respectively 
[164]. PKR activity is increased in adipose tissue and liver of murine model of obesity [165]. 
With its ability to respond to pathogens, nutrients and organelle stress, PKR appears to be core 
component of inflammatory and immune pathways. However, depending on which key factor 
is activated downstream, that is, either NF-κB (pro-apoptotic) or eIF2α (anti-apoptotic), PKR 
may “serve as molecular clock to time the sequential events of survival and death” [166]. In 
summary, PKR affirms the complexity of UPR signaling and its downstream outcomes [120].




CREBH is a transcription factor belonging to CREB/ATF family of transcription factor and 
is required for liver synthesis of Amyloid P-component and CRP [167]. CREBH is activated 
via RIP process (Regulated Intramembrane Proteolysis: release and transport of ER resi-
dent protein from the ER membrane to Golgi for processing) upon ER stress. Other than 
ER stress, TNFα, Interleukin 6 (IL6) and lipoprotein LPS also induce expression of CREBH 
[168]. This makes room for another revelation: ER stress in the liver may be linked to sys-
temic inflammation via the RIP- mediated mobilization of CREBH [120].
6.5.2. ER stress and apoptosis
Apoptosis is an important component of disease progression in NAFLD [169] and is posi-
tively correlated with disease severity in NASH [24]. The failure of UPR in mitigating the ER 
stress leads to cell death via several mechanisms (Figure 4).
CHOP is one of the best characterized UPR-regulated pro-apoptotic protein [120]. CHOP is 
an ER-derived transcription factor activated downstream from PKR- and ATF6-pathway of 
UPR. Significance of CHOP in inducing apoptosis can be emphasized from results of study 
where silencing CHOP lead to decreased hepatocyte apoptosis in alcohol-induced liver dis-
ease [130] and attenuated cholestasis-induced liver fibrosis [170]. However, the role of CHOP 
is paradoxical in NAFLD, as demonstrated in study where CHOP deletion can reduce palmi-
tate-induced apoptosis in hepatocyte cell line, whereas MCD diet-induced apoptosis was not 
reduced in CHOP knockout mice [171, 172].
CHOP has been described as an unstable protein compared to other protein chaperons like 
GRP78 [120]. Above described paradoxical role of CHOP in NAFLD makes way for observa-
tion: role of CHOP as a pro-apoptotic protein may be dependent on level of CHOP expres-
sion, the presence of factors which increase stability and/or protein–protein interactions 
that direct cell specific effects [173, 174]. Hence, future studies regarding role of CHOP in 
mice model are needed to elicit exact contributions of CHOP towards disease progression in 
NAFLD and NASH.
Furthermore, The IRE1 branch of the UPR, via its activation of JNK and Caspase 12 [175], 
and its interaction with Bax and Bak (two pro-apoptotic Bcl2 family members) [176], can also 
activate path towards apoptosis.
Additionally, another mechanism proposed for hepatic cell apoptosis is dysregulation in ER 
calcium flux. The ER calcium flux is regulated by ER stress, ER-localized protein and BCL-2 
proteins interacting with other ER-localized proteins [177, 178]. The ERO1α-mediated activa-
tion of IP3, as mentioned earlier, can lead to disruption of ER calcium homeostasis [132]. This disruption inhibits sarco-endoplasmic reticulum Ca2+-ATPase uptake pump, decreasing the 
folding capacity of ER, and hence, can induce ER stress and apoptosis [179]. Truncated vari-
ants of sarco-endoplasmic reticulum Ca2+-ATPase have also been implicated in dysregulation 
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of Calcium flux [180]. Subsequently, the release of ER calcium and its uptake in mitochon-
dria leads to mitochondrial membrane permeabilization, and activation of intrinsic apoptotic 
pathway. Recent studies also suggest that Smooth and Rough ER may be physically and func-
tionally interacting with mitochondria via tethers and reduction in lengths of these tethers in 
response to pro-apoptotic agents might be one mechanism for apoptosis [181, 182].
7. Genetic factors
A possible explanation for observed inter-individual variability in susceptibility to NAFLD 
and progressive NASH is provided by genetics. Patatin-like phospholipase domain-containing 
Figure 4. Different mechanisms for ER stress-induced apoptosis [135] (https://doi.org/10.1016/j.jhep.2010.11.005) (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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3 (PNPLA3), also called adiponutrin, is a protein expressed on endoplasmic reticulum, and 
on lipid droplets in hepatocytes and adipocytes [183]. It is activated after feeding and is the 
master regulator of lipogenesis by SREBP-1c. The 148 M variant of PNPLA3 is associated with 
increased expression of lipogenic transcription factor SREBP1c and alters the lipid catabolism 
[184]. The 148 M variant is associated with increased severity of NAFLD. In another study, 
patients with 148 M variant in genotype developed increased steatosis, with augmented lobu-
lar inflammation, hepatocellular ballooning and NASH [185].
7.1. Epigenetic modifications
Epigenetic modifications, mainly including microRNA, DNA methylation, histone modifica-
tion and ubiquination, refers to phenotypic changes irrespective of changes to underlying 
DNA. “miRNA” are small single stranded RNA molecules regulating mRNA degradation 
or translation inhibition, subsequently altering protein expression of target genes [186]. The 
miR-122, which accounts for 70% of all miRNA in the liver, is significantly under-expressed 
in NASH subjects compared to normal subjects [187]. Inhibition of miR-122 via antisense oli-
gonucleotide in diet-induced obesity mouse models resulted in decreased mRNA expression 
of acetyl-CoA carboxylase-2, fatty acid synthase, SREBP1c, Stearoyl-CoA desaturase, all of 
which are key lipogenic factors in human NASH, and the histology showed marked improve-
ment in liver steatosis [188]. In another study in mice, the plasma cholesterol level, hepatic 
fatty acid and cholesterol synthesis rate as well as HMG CoA reductase level were all signifi-
cantly reduced after silencing miR-122 [189]. These findings strongly suggest the significance 
miR-122 in the regulation of lipid metabolism. Besides miR-122, miR-34a and miR-146b were 
shown to be significantly over-expressed in human NASH [187].
Similarly, aberrant methylation patterns of genomic DNA have been linked to NAFLD. A 
recent study found positive correlation between NAFLD and hepatic DNA methylation of 
GpC in PPAR-δ and mitochondrial transcription factor A (TFAM), with methylation being 
higher in NAFLD liver as compared to control [190]. In conclusion, genetic and epigenetic 
factors interact with other determinants to produce NAFLD phenotype and determine the 
rate of its progression [187].
8. Conclusion
The above laborious and detailed discussion on complex molecular mechanisms associated 
with disease progression in NAFLD does point towards the fact: The pathogenesis and pro-
gression of disease in NAFLD is complex interplay of different hormonal, immunological, 
metabolic, genetic and environmental components. Each component can act on its own or act 
in concert with other culprits to causes augmented damage to liver. However, more studies 
are needed to uncover the still unknown players, and to understand the interactions between 
the different players of multiple-hit model.
Non-Alcoholic Fatty Liver Disease - Molecular Bases, Prevention and Treatment36
Appendix
ACC  acetyl-CoA carboxylase
AhR  aryl hydrocarbon receptor
AMPK  cyclin AMP dependent protein kinase
AP-1  activating protein-1
ASK1  apoptotic signal kinase-1
ATF6  activating transcription factor 6
CDAA diet choline-deficient, amino acid defined diet
CHOP  CCAAT-enhancer-binding protein homologous protein
ChREBP  carbohydrate response element-binding protein
CREB  cAMP response element-binding protein
DAMP  danger associated molecular pattern
DGAT  diacylglycerol transferase
DR5  death receptor 5
eIF-2α  eukaryotic initiation factor-2α
ER  endoplasmic reticulum
Ero 1 α  endoplasmic reticulum oxidoreductase 1
Fiaf  fasting-induced adipocyte factor
FXR  farnesoid X receptor
GADD  growth arrest and DNA damage
HNE  4-hydroxy-2-noneal
IKKb  Inhibitor of nuclear factor kappa-B kinase subunit beta
Insigs  insulin regulated proteins
IRE 1  inositol-requiring ER-to-nucleus signaling protein1
IRS  insulin receptor substrate
JNK  Jun N-terminal Kinase




MAP  mitogen-activated protein
MAPK  mitogen-activated protein kinase
mTOR  mechanistic target of rapamycin
NAFLD  nonalcoholic fatty liver disease
NALP  NACHT, LRR and PYD domains-containing protein 3
NF-κB  nuclear factor κ beta
NLR  nod-like receptor
NLRP  NLR family, pyrin domain-containing 3 inflammasomes
Nrf2  nuclear factor-erythroid-derived 2-related factor 2
PERK  protein kinase RNA- like endoplasmic reticulum kinase
PKC-γ  protein kinase C-gamma
PKR  RNA activated protein kinase
PNPLA3 patatin-like phospholipase domain-containing 3
PPAR  peroxisome proliferator activated receptor
ROS  reactive oxygen species
SCAP  SREBP-cleavage activating proteins
SCD1  stearoyl-CoA desaturase-1
SCFA  short chain fatty acid
SOCS  suppressor of cytokine signaling
SREBP  sterol regulatory element-binding protein
TBARS  thiobarbituric acid reacting substrate
TFAM  mitochondrial transcription factor A
TGF-β1  transforming growth factor-β1
TLR  toll-like receptor
TNF  tumor necrosis factor
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TNFR  tumor necrosis factor receptor
TRAIL  TNF-related apoptosis-inducing ligand
UPR  unfolded protein response
XBP1  X-box binding protein-1
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